List view / Grid view
7 May 2015 | By Victoria White
University of British Columbia researchers have reported that a new anticonvulsant epilepsy drug holds promise as a treatment for Alzheimer’s disease...
29 April 2015 | By Victoria White
Inhibiting HDACs has shown significant potential in stimulating the growth of brain cells and memory restoration in animal models that mimic Alzheimer’s...
28 April 2015 | By Victoria White
A new function now described for the protein dDsk2 links ubiquitin receptors for the first time with the regulation of gene expression...
7 April 2015 | By Victoria White
Edaravone, a drug used to treat stroke victims, could help stop the progression of Alzheimer’s Disease according to new research...
20 March 2015 | By Victoria White
Probiodrug has announced that the company will present data on its specific pGlu-Abeta mouse antibody 17/1 at AD/PDTM 2015 in Nice, France...
9 March 2015 | By Probiodrug
First patient enrolled at leading Alzheimer Center in Amsterdam...
3 March 2015 | By Probiodrug
Strong correlation between QCs and AD pathology in human brain biopsies underlines QC-inhibition as therapeutic approach...
18 February 2015 | By Alzheimer’s Research UK
Institutes at Universities of Cambridge, Oxford and UCL will form £30m Drug Discovery Alliance...
28 January 2015 | By GlobalData
While current treatments for Alzheimer’s Disease are only able to ease symptoms temporarily, tau-based vaccines may offer a new and more effective way to treat AD in the early course of the disease, says an analyst with research and consulting firm GlobalData...
2 December 2014 | By MRC Technology
MRC Technology and Shandong International Biotechnology Park (BIOasis) have signed a partnership agreement for the development of a new Alzheimer’s drug...
29 October 2014 | By Probiodrug AG
Probiodrug AG, a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, has announced it is the Silver sponsor of the 5th Biannual NUBIN Symposium on Biomarkers in Neurodegenerative Disease taking place on October 29th and 30th in Amsterdam.
25 September 2014 | By Probiodrug
Probiodrug AG announces its intention to raise new funds through an Initial Public Offering and listing on Euronext Amsterdam...
17 July 2014 | By Roche
Roche presented data from two phase II studies investigating whether crenezumab can delay cognitive and functional decline in people with mild-to-moderate Alzheimer’s disease...
3 April 2014 | By Daiichi Sankyo
Daiichi Sankyo Co., Ltd. and University of California, San Francisco announced that they have established a drug discovery collaboration focused on developing novel therapeutics and molecular diagnostics for multiple neurodegenerative diseases...
5 March 2014 | By Biogen Idec
Eisai Co., Ltd. and Biogen Idec announced that they have entered into a collaboration to develop and commercialize two of Eisai’s clinical candidates for Alzheimer’s disease, E2609 and BAN2401...
